摘要
目的探讨腔内治疗或血管旁路术治疗头臂型大动脉炎的疗效。方法回顾性分析2005~2019年我科33例头臂型大动脉炎的临床资料,其中19例采用腔内治疗(球囊扩张),14例采用动脉旁路术,观察2组患者术后血栓形成、缺血-再灌注损伤、心功能不全、肺部感染及血管通畅等情况。结果33例手术均成功,无死亡病例。随访3~135个月,1例血管旁路术后5个月脑出血死亡,1例腔内治疗术后13个月死于鼻咽癌,1例腔内治疗术后第3个月失访。旁路手术组3、6个月和1、3、5、10年通畅率分别为100.0%(14/14)、92.3%(12/13)、92.3%(12/13)、92.3%(12/13)、92.3%(12/13)、76.9%(10/13),腔内治疗分别为94.4%(17/18)、88.9%(16/18)、83.3%(15/18)、58.8%(10/17)、52.9%(9/17)、52.9%(9/17)。结论血管旁路手术或腔内治疗臂型大动脉炎疗效满意。
Objective To explore the efficacy of endovascular interventional and bypass therapy for typeⅠTakayasu’s arteritis.Methods A total of 33 cases of endovascular interventional or bypass therapy were carried out from 2005 to 2019.All the patients were diagnosed as typeⅠTakayasu’s arteritis.Among them,19 cases were treated with endovascular therapy(balloon dilatation),and 14 cases were treated with arterial bypass.The postoperative thrombosis,ischemia-reperfusion injury,cardiac insufficiency,pulmonary infection and vascular patency were observed in the two groups.Results The operations were successful in all the 33 cases and no death occurred.The 33 patients were followed up for 3-135 months.At follow-ups,1 case died of cerebral hemorrhage 5 months after arterial bypass,1 case died of nasopharyngeal carcinoma 13 months after endovascular therapy,and 1 case of endovascular therapy was lost to follow-up at 3 months postoperatively.The bypass therapy patency rates for 3-month,6-month,1-year,3-year,5-year,and 10-year were 100.0%(14/14),92.3%(12/13),92.3%(12/13),92.3%(12/13),92.3%(12/13),and 76.9%(10/13);whereas the endovascular therapy patency rates were 94.4%(17/18),88.9%(16/18),83.3%(15/18),58.8%(10/17),52.9%(9/17),and 52.9%(9/17).Conclusion Endovascular interventional or bypass therapy is safe and effective for typeⅠTakayasu’s arteritis.
作者
刘一人
郭连瑞
崔世军
齐立行
佟铸
郭建明
谷涌泉
Liu Yiren;Guo Lianrui;Cui Shijun(Department of Vascular Surgery,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)
出处
《中国微创外科杂志》
CSCD
北大核心
2020年第7期604-607,共4页
Chinese Journal of Minimally Invasive Surgery
基金
国家重点研发计划项目(2017YFC1104100)
北京市属医院科研培育计划(PX2018035)
首都医科大学宣武医院院级课题(XWJL-2019032)。
